In his role at Pontifax, Ohad is also involved in the formation and development strategy of the fund’s early-stage portfolio companies.
He serves as a director in Agomab and Emergence Therapeutics.
![](https://step-ph.com/wp-content/uploads/2022/07/SPT_Ohad_Hammer.jpg)
![client](https://step-ph.com/wp-content/uploads/2022/07/SP_I_Sunstone.jpg)
![client](https://step-ph.com/wp-content/uploads/2022/07/SP_I_Signature.jpg)
![client](https://step-ph.com/wp-content/uploads/2022/07/SP_I_Pontifax.jpg)
![client](https://step-ph.com/wp-content/uploads/2022/07/SP_I_Kurma.jpg)
![client](https://step-ph.com/wp-content/uploads/2022/07/SP_I_Inserm.jpg)
![client](https://step-ph.com/wp-content/uploads/2022/07/SP_I_Imagine.jpg)
![client](https://step-ph.com/wp-content/uploads/2022/07/SP_I_idinvest.jpg)
![client](https://step-ph.com/wp-content/uploads/2022/07/SP_I_Hadean.jpg)
![client](https://step-ph.com/wp-content/uploads/2022/07/SP_I_bpifrance.jpg)
In his role at Pontifax, Ohad is also involved in the formation and development strategy of the fund’s early-stage portfolio companies.
He serves as a director in Agomab and Emergence Therapeutics.